Navigation Links
Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
Date:9/30/2010

RESEARCH TRIANGLE PARK, N.C., Sept. 30 /PRNewswire/ -- A global pharmaceutical company has initiated a prospective trial to evaluate the impact of insulin guidelines developed by the Indian National Consensus group in collaboration with Max Neeman, a leading India-based Contract Research Organization. The goal is to provide simple management to the Type II Diabetes patient dependent on insulin.  The study will bring out a comparison between the routine clinical practice and the therapy decided as per the Insulin guidelines.

This large Phase IV study encompasses the northern, southern, western and eastern parts of India with over 1,200 sites and aims to enroll over 25,000 Type II Diabetics. Max Neeman is responsible for site management of all locations across the country and for achieving the enrollment target. To date, the team has successfully enrolled over 12,000 patients in 2 months time and will achieve the target before the stipulated time.

Max Neeman is experienced in endocrinology/metabolic studies having been awarded numerous diabetic trials to date with 98% patient retention rate and target enrollment met by the deadline.

About Max Neeman International

Max Neeman International is one of the leading CROs in India. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in over 31 cities with 6 regional offices.  Contact Donald Swankie, Vice President of Business Development via email to donald.swankie@neeman-medical.com or call +1.919.424.3345.  For more information please visit www.neeman-medical.com.


'/>"/>
SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
2. Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model
3. Max Neeman International and AMEDON Collaborate to Increase EDC Performance
4. Max Neeman International Expands Specialized Surgical Team for Clinical Trials
5. International Robotic Urology Symposium 2011
6. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
7. Mindray Medical to Exhibit New Products at 64th China International Medical Equipment Fair
8. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
9. Webmedx and NLP International Team to Bring Natural Language Processing Software to Medical Transcription
10. MedWOW International Medical Equipment Platform Adds Seller Ministores
11. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017  Ethicon* today announced the completion of ... held medical device company that manufactures and markets ... treatment of Gastroesophageal Reflux Disease (GERD). This acquisition ... portfolio of minimally invasive options for patients suffering ... of the transaction have not been disclosed. ...
(Date:3/23/2017)... YORK , March 23, 2017 ... sample preparation market is expected to reach USD 7.2 billion ... of 7.1%. Sample preparation is a procedure in which a ... crucial step in most analytical procedures since the methods are ... preparation is one of the most shared procedures in the ...
(Date:3/23/2017)... 2017  Drug diversion is a significant contributing ... overdoses. A new oral fluid monitoring test, announced ... reports more detailed and actionable information to clinicians ... therapy adherence, patient safety, and help to identify ... fluid Rx Evaluation (CORE) system is the first ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... After raising more than $1.135 million ($1,479,231 AUD) ... travel pillow in crowdfunding history, has established a U.S. Headquarters in New York ... to Americans. , “We’re excited to be operating on U.S. shores, where most of ...
(Date:3/23/2017)... ... ... conference will prominently feature 150+ Hospital and Health System Executive Speakers including: , ... 43rd President of the United States of America: George W. Bush , ... the Ring: Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber McGraw Walsh ...
(Date:3/23/2017)... ... March 23, 2017 , ... Sharon Kleyne, host of the nationally syndicated ... Health on VoiceAmerica, recently talked on her program about how she is looking forward ... remind listeners of an important distinction. World Water Day, Kleyne pointed out, is an ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... help improve all aspects of people’s health and nutrition, announced its product Leyzene ... , Natural Subsistence develops nutritional supplements that help people improve all aspects ...
(Date:3/23/2017)... ... ... Inflow IQ & Inflownomics of Raleigh, NC introduce a powerful information access network. ... experts in dangerous situations the Inflow IQ team can help people. Get ready ... & refreshing knowledge systems that enhance life. , Authentically enjoy 500 ...
Breaking Medicine News(10 mins):